| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GP1BB |
| Uniprot No | P13224-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-147aa |
| 氨基酸序列 | MGSGPRGALS LLLLLLAPPS RPAAGCPAPC SCAGTLVDCG RRGLTWASLP TAFPVDTTEL VLTGNNLTAL PPGLLDALPA LRTAHLGANP WRCDCRLVPL RAWLAGRPER APYRDLRCVA PPALRGRLLP YLAEDELRAA CAPGPLC |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GP1BB重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Recombinant expression and functional characterization of human platelet glycoprotein Ibβ (GP1BB) in a mammalian cell system*
**作者**：Li R, Emsley J
**摘要**：该研究通过哺乳动物细胞系统成功表达了具有生物活性的重组人GP1BB蛋白，并验证了其与GPIX亚基的相互作用。实验表明，重组GP1BB能恢复GPIb-IX复合体缺陷型细胞的表面表达，为研究血小板功能异常疾病(如Bernard-Soulier综合征)提供了工具。
---
2. **文献名称**：*Structural insights into GP1BB mutations causing Bernard-Soulier syndrome*
**作者**：Kanaji T, Russell SR
**摘要**：作者利用重组GP1BB蛋白解析了其晶体结构，揭示了关键突变位点对GPIb-IX复合体稳定性的影响。通过体外结合实验，发现某些突变会导致GP1BB与血管性血友病因子(vWF)的相互作用受损，解释了血小板黏附功能缺陷的分子机制。
---
3. **文献名称**：*A recombinant GP1BB fusion protein enhances platelet production in a murine model of thrombocytopenia*
**作者**：Machlus KR, Italiano JE
**摘要**：研究开发了一种重组GP1BB与TPO(血小板生成素)的融合蛋白，并在血小板减少症小鼠模型中验证其疗效。结果显示，该蛋白能特异性结合巨核细胞受体并促进血小板生成，为开发靶向血小板疾病疗法提供了新思路。
---
**备注**：以上文献为示例性内容，实际研究中建议通过PubMed或Web of Science检索最新论文。GP1BB研究多聚焦于血小板功能、遗传性疾病(如Bernard-Soulier综合征)及靶向治疗策略。
The GP1BB recombinant protein is a biologically engineered form of the glycoprotein Ib beta subunit (GP1BB), a critical component of the platelet membrane glycoprotein Ib-IX-V complex. This complex plays a central role in primary hemostasis by mediating platelet adhesion to von Willebrand factor (vWF) at sites of vascular injury. GP1BB, encoded by the GP1BB gene, stabilizes the complex and ensures proper surface expression of the GPIbα subunit, which directly binds vWF under shear stress. Structurally, GP1BB belongs to the leucine-rich glycoprotein family, featuring a leucine-rich repeat (LRR) domain, a transmembrane region, and a cytoplasmic tail. Recombinant GP1BB is typically produced using expression systems like mammalian cells (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and functionality.
Research applications of GP1BB recombinant protein span platelet biology studies, drug discovery, and disease modeling. It serves as a tool to investigate molecular mechanisms in thrombotic disorders or bleeding diatheses like Bernard-Soulier syndrome (BSS), a rare inherited bleeding disorder linked to GP1BB mutations. In drug development, the protein aids in screening therapeutic candidates targeting platelet aggregation pathways, particularly for anti-thrombotic therapies. Additionally, it supports diagnostic assay development for platelet-related pathologies. Emerging studies explore its potential in gene therapy vectors for BSS treatment. The recombinant form's controlled production ensures batch-to-batch consistency, enabling reliable experimental outcomes. As platelet dysfunction research advances, GP1BB recombinant protein remains pivotal in bridging molecular insights to clinical applications.
×
